The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. James L. Gulley on Atezolizumab, Pembrolizumab, and Avelumab's Potential Uses in Bladder Cancer

James L. Gulley, MD, PhD
Published Online: 2:18 PM, Mon January 11, 2016

James L. Gulley, MD, PhD, chief of the Genitouriniy Malignancies Branch, director of Medical Oncology Service, National Cancer Institute, discusses the potential shift of the treatment paradigm in bladder cancer. Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer.

Gulley says data from phase III trials suggests acitivity in bladder cancer from treatments such as atezolizumab, pembrolizumab, and avelumab. Gulley adds that if these treatments pan out to be as useful as researchers believe they are, oncologists then must determine when to employ them throughout treatment in bladder cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.